Core Insights - Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer, specifically for clinically proven kinase targets [3] - The company will participate in the Cantor Global Healthcare Conference 2025, with CEO James Porter and CFO Alexandra Balcom scheduled for a fireside chat on September 4, 2025 [1] Company Overview - Nuvalent specializes in creating precisely targeted therapies aimed at overcoming the limitations of existing cancer treatments [3] - The company utilizes expertise in chemistry and structure-based drug design to develop innovative small molecules that can address issues such as resistance, adverse events, and brain metastases [3] - Nuvalent is advancing a pipeline that includes investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, along with multiple discovery-stage research programs [3]

CAMBRIDGE, Mass., April 1, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Stifel 2025 Virtual Targeted Oncology Forum on Tuesday, April 8, 2025, at 2:30 p.m. ET. A live webcast will be available in the Inve ...